Overview

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

Status:
Recruiting

Trial end date:
2023-11-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Entecavir
Peginterferon alfa-2a
Tenofovir